| Literature DB >> 21978659 |
Tamaki Takano1, Yoshinori Ohtsu, Takamitsu Terasaki, Yuko Wada, Jun Amano.
Abstract
Although Staphylococcus capitis is considered to be a rare causative organism for prosthetic valve endocarditis, we report 4 such cases that were encountered at our hospital over the past 2 years. Case 1 was a 79-year-old woman who underwent aortic valve replacement with a bioprosthetic valve and presented with fever 24 days later. Transesophageal echocardiography revealed an annular abscess in the aorto-mitral continuity and mild perivalvular regurgitation. We performed emergency surgery 5 days after the diagnosis of prosthetic valve endocarditis was made. Case 2 was a 79-year-old woman presenting with fever 40 days after aortic valve replacement with a bioprosthesis. Transesophageal echocardiography showed vegetation on the valve, and she underwent urgent surgery 2 days after prosthetic valve endocarditis was diagnosed. In case 3, a 76-year-old man presented with fever 53 days after aortic valve replacement with a bioprosthesis. Vegetation on the prosthetic leaflet could be seen by transesophageal echocardiography. He underwent emergency surgery 2 days after the diagnosis of prosthetic valve endocarditis was made. Case 4 was a 68-year-old woman who collapsed at her home 106 days after aortic and mitral valve replacement with bioprosthetic valves. Percutaneous cardiopulmonary support was started immediately after massive mitral regurgitation due to prosthetic valve detachment was revealed by transesophageal echocardiography. She was transferred to our hospital by helicopter and received surgery immediately on arrival. In all cases, we re-implanted another bioprosthesis after removal of the infected valve and annular debridement. All patients recovered without severe complications after 2 months of antibiotic treatment, and none experienced re-infection during 163 to 630 days of observation. Since the time interval between diagnosis of prosthetic valve endocarditis and valve re-replacement ranged from 0 to 5 days, early surgical removal of the infected prosthesis and an appropriate course of antibiotics were attributed to good clinical outcomes in our cases.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21978659 PMCID: PMC3199242 DOI: 10.1186/1749-8090-6-131
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Patient characteristics
| Age | Sex | PVE onset from the first operation (Days) | First valve operation | Surgical Indication | Fever at admission | Heart | Embolic Event | Re-operation from the PVE diagnosis (days) | Re-operation from the fever onset (days) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 79 | F | 24 | AVR (Biological) | Annular abscess | + | - | - | 5 | 12 | |
| 79 | F | 40 | AVR (Biological) | Vegetation | + | - | - | 2 | 14 | |
| 76 | M | 53 | AVR (Biological) | Vegetation | + | - | - | 2 | 8 | |
| 68 | F | 106 | MVR (Biological) | Regurgitation | + | + | - | 0 | 8 | |
| 76 ± 5.2 | 56 ± 36 | 2.3 ± 2.1 | 10.5 ± 3 | |||||||
PVE; prosthetic valve endocarditis, F; female, M; male AVR; aortic valve replacement, MVR; mitral valve replacement
Antibiotics Susceptibility
| PCG | MPIPC | CEZ | IPM | GM | ABK | EM | CLDM | MINO | LVFX | FOM | VCM | ST | TEIC | LZD | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| > = 0.5 | > = 4 | < = 4 | < = 1 | 8 | < = 1 | < = 0.25 | < = 0.25 | < = 0. 5 | 0.5 | > = 128 | < = 1 | < = 10 | < = 0.5 | N/A | |
| > 8 | > 2 | > 16 | 2 | > 8 | < = 1 | 0.5 | < = 0.5 | < = 1 | 1 | > 16 | < = 2 | < = 2 | < = 2 | < = 2 | |
| > = 0.5 | > = 4 | 8 | < 1 | 8 | < = 1 | < = 0.25 | < = 0.25 | < = 0. 5 | 1 | > = 128 | 1 | N/A | < = 0.5 | 2 | |
| > 8 | > 2 | > 16 | 4 | > 8 | < = 1 | < = 0.25 | < = 0.5 | < = 1 | < = 0.5 | > 16 | < = 2 | < = 2 | < = 2 | < = 2 | |
PCG; penicillin G, MPIPC; oxacillin, CEZ; cephazolin, IPM; imipenem, GM; gentamicin, ABK; arbekacin, EM; erythromycin, CLDM; clindamycin, MINO; minocycline, LVFX; levofloxacin, FOM; fosfomycin, VCM; vancomycin, ST; sulfamethoxazole-trimethoprim, TEIC; teicoplanin, LZD; linezolid, N/A; not available
Figure 1Operative Findings in Case 1. Yellowish-white film covered the entire Carpentier-Edwards Magna bioprosthesis, and vegetation located on the right coronary cusp. Valve dehiscence was found at the commissure between the left and non-coronary cusp.
Figure 2Operative Findings in Case 1. Intimal defect was repaired with autologous pericardial patch after the debridement.
Re-operation procedure, Antibiotics and Re-infection
| Annular abscess | Re-operation Procedure | Prosthesis | Intravenous antibiotics | Oral antibiotics | Observation period (days) | Survive | |
|---|---|---|---|---|---|---|---|
| Case 1 | + | Abscess isolation | Biological | AMK→ LZD→TEIC | MINO | 630 | + |
| Case 2 | - | AVR | Biological | VCM | MINO | 332 | + |
| Case 3 | + | Valve annuls reconstruction | Biological | TEIC→VCM→LZD | LVFX | 224 | + |
| Case 4 | + | Valve annuls reconstruction | Biological | VCM+GM | LVFX | 163 | + |
AVR; aortic valve replacement, AMK; Amoxicillin, LZD; linezolid, TEIC; teicoplanin, MINO; minocycline, VCM; vancomycin, LVFX; levofloxacin, MVR; mitral valve replacement, GM; gentamicin.
Figure 3Operative Findings in Case 2. Carpentier-Edwards Magna valve was covered by white and yellowish thin film, and vegetations were attached on the stent and prosthetic leaflet.
Figure 4Operative Findings in Case 3. The bioprosthetic valve was totally detached from the annulus.
Figure 5Operative Findings in Case 3. The defect of the aortic annulus and aortic wall was repaired with Gelweave graft patch after annular abscess debridement.
Figure 6Operative Findings in Case 4. Yellowish white film covered the whole mitral valve, and valve detachment had occurred at the 1/3 of the annulus.